Tacere Therapeutics, Inc.
5941 Optical Court
San Jose
California
95138
United States
Tel: 408-960-2205
Fax: 408-960-2207
Website: http://www.tacerebio.com/
Email: info@tacerebio.com
7 articles about Tacere Therapeutics, Inc.
-
Benitec, Inc. Announces Acquisition of Tacere Therapeutics, Inc. and Phase I/II Ready Hepatitis C (HCV) Program
10/11/2012
-
Tacere Therapeutics, Inc. Reacquires Rights to Develop and Commercialize its Hepatitis C Compounds in Asia from Oncolys BioPharma
2/4/2011
-
Exiqon A/S Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics, Inc.
9/15/2009
-
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer Inc. To Develop and Commercialize RNAi Hepatitis C Drug
1/7/2008
-
Oncolys BioPharma and Tacere Therapeutics Form Strategic Alliance to Develop RNAi Hepatitis C Drug
6/21/2007
-
Tacere Therapeutics Appoints Vice President, Research And Development
11/14/2006
-
Tacere Therapeutics Secures Financing And Resumes Development Of RNAi Hepatitis C Drug
10/12/2006